{
  "hypothesis": "h242",
  "title": "Biologic Precision Rescue via Mechanism Tiers",
  "outcome": "PARTIALLY_VALIDATED",
  "summary": {
    "overall_biologic_precision": 2.6,
    "high_confidence_precision": 5.9,
    "target_threshold": 20,
    "mechanism_classes_above_threshold": 0
  },
  "mechanism_class_precision": {
    "IL-17 inhibitors": {
      "precision": 50.0,
      "count": 2,
      "note": "Too few predictions to be actionable"
    },
    "JAK inhibitors": {
      "precision": 16.7,
      "count": 18,
      "note": "Close to threshold"
    },
    "CD20 (B-cell)": {
      "precision": 12.5,
      "count": 24
    },
    "TNF inhibitors": {
      "precision": 9.3,
      "count": 43
    },
    "IL-6 inhibitors": {
      "precision": 5.6,
      "count": 36
    },
    "CTLA-4/PD-1/PD-L1": {
      "precision": 5.9,
      "count": 17
    }
  },
  "disease_specific_success": {
    "rheumatoid_arthritis": {
      "precision": 33.3,
      "count": 6
    },
    "psoriatic_arthritis": {
      "precision": 33.3,
      "count": 6
    },
    "melanoma": {
      "precision": 33.3,
      "count": 3
    },
    "temporal_arteritis": {
      "precision": 25.0,
      "count": 4
    },
    "psoriasis_vulgaris": {
      "precision": 20.0,
      "count": 5
    },
    "crohns_disease": {
      "precision": 18.2,
      "count": 11
    }
  },
  "root_cause": {
    "finding": "GT SPARSITY - not mechanism failure",
    "evidence": {
      "biologics_10_drugs": {
        "gt_entries": 58,
        "pct": 0.1
      },
      "small_molecules_comparison": {
        "prednisone": 271,
        "methotrexate": 275,
        "cyclosporine": 232,
        "prednisolone": 268,
        "adalimumab": 4,
        "rituximab": 6
      }
    },
    "explanation": "Biologics have 50x fewer GT entries than small molecules. This is expected: biologics are newer, more expensive, and less broadly prescribed."
  },
  "key_findings": [
    "No mechanism class achieves >=20% precision overall",
    "IL-17 inhibitors hit 50% but only 2 predictions (not actionable)",
    "JAK inhibitors are closest at 16.7% (18 predictions)",
    "For KNOWN SUCCESS DISEASES (RA, PsA, melanoma), precision reaches 33%",
    "Root cause is GT sparsity: 10 biologics have 58 GT entries vs prednisone alone has 271",
    "DISEASE-SPECIFIC routing may help: filter biologics to only RA, PsA, IBD, melanoma, etc."
  ],
  "recommendations": [
    "Do NOT exclude biologics entirely - they ARE correct for certain diseases",
    "Consider disease-specific biologic routing: only predict biologics for known success diseases",
    "JAK inhibitors are borderline acceptable (16.7%) for autoimmune diseases",
    "Checkpoint inhibitors should only be predicted for cancer"
  ]
}